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Abstract
Secundum-type atrial septal defects (ASDII) account for approximately 10% of all congenital heart defects (CHD) and are
associated with a familial risk. Mutations in transcription factors represent a genetic source for ASDII. Yet, little is known
about the role of mutations in sarcomeric genes in ASDII etiology. To assess the role of sarcomeric genes in patients with
inherited ASDII, we analyzed 13 sarcomeric genes (MYH7, MYBPC3, TNNT2, TCAP, TNNI3, MYH6, TPM1, MYL2, CSRP3, ACTC1,
MYL3, TNNC1, and TTN kinase region) in 31 patients with familial ASDII using array-based resequencing. Genotyping of
family relatives and control subjects as well as structural and homology analyses were used to evaluate the pathogenic
impact of novel non-synonymous gene variants. Three novel missense mutations were found in the MYH6 gene encoding
alpha-myosin heavy chain (R17H, C539R, and K543R). These mutations co-segregated with CHD in the families and were
absent in 370 control alleles. Interestingly, all three MYH6 mutations are located in a highly conserved region of the alpha-
myosin motor domain, which is involved in myosin-actin interaction. In addition, the cardiomyopathy related MYH6-A1004S
and the MYBPC3-A833T mutations were also found in one and two unrelated subjects with ASDII, respectively. No mutations
were found in the 11 other sarcomeric genes analyzed. The study indicates that sarcomeric gene mutations may represent a
so far underestimated genetic source for familial recurrence of ASDII. In particular, perturbations in the MYH6 head domain
seem to play a major role in the genetic origin of familial ASDII.
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Introduction
Congenital heart defects (CHD) are the most common inborn
malformations and are a major cause of perinatal mortality.
Though the etiology of CHD is largely unknown, epidemiological
studies indicate a genetic component [1]. The ostium secundum
atrial septal defect (ASDII) accounts for 10% of all CHD and
shows familial recurrence in approximately 8% [2]. In recent
years, single gene mutations were identified as heritable risk factors
for familial ASDII [3]. Though mutations in cardiac transcription
factors are believed to represent a major genetic source for ASDII,
mutations in non-regulatory genes were also found [3]. In patients
with familial ASDII, pedigree based linkage analyses identified
mutations in MYH6 and ACTC1, which encode the sarcomeric
filament proteins alpha-myosin heavy chain and cardiac alpha-
actin, respectively [4,5]. Sarcomeric genes are well recognized as
disease genes for diverse familial cardiomyopathies [6]. So far,
more than ten different sarcomeric genes have been classified as
cardiomyopathy disease genes. A subset of patients with familial
dilated cardiomyopathy (DCM) harbors additional cardiac
anomalies including ASDII [7]. ASDII was also reported to be
overrepresented in patients with hypertrophic cardiomyopathy
(HCM) or left-ventricular non-compaction cardiomyopathy
(LVNC) caused by mutations in ACTC1 and MYH7 encoding
the sarcomeric filaments alpha-actin and beta-myosin heavy chain,
respectively [8,9]. Moreover, recent studies have reported
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and MYH7 mutations in congenital Ebstein anomaly in combina-
tion with LVNC [11].
To systematically investigate the role of sarcomeric cardiomy-
opathy disease genes as a genetic source for ASDII, we analyzed
the coding region of 13 sarcomeric genes using array-based
resequencing technology in 31 patients with proven familial
ASDII. In the present study, we provide further evidence for a
connection between CHD and the sarcomere, especially the thick
filamentous alpha-myosin heavy chain.
Results
Thirty-one patients with proven familial ASDII were investigat-
ed.Thenumberoffamily membersaffectedby CHD rangedfrom 2
to 12 (mean 3.7). Mutations in NKX2.5 and GATA4 were previously
excluded in all probands. In total, 205 sequence variations including
134 intronic and 71 exonic (of these 13 non-synonymous and 58
synonymous) variations were found among 16 genes (Supporting
data S1). These comprised mostly known single nucleotide
polymorphisms (SNPs) registered in DB SNP and or exome variant
server (EVS) [12]. After careful bioinformatic analysis we extracted
five distinct rare mutations (four MYH6 and one MYBPC3
mutations) in six unrelated ASDII index patients. All mutations
were heterozygous missense mutations. Three MYH6 mutations
were novel and two (one MYH6 and one MYBPC3) were previously
found in patients with familial cardiomyopathies. The mutations
were absent in 370 control alleles from ethnically matched
individuals without CHD. Moreover, the three novel MYH6
mutations were not found among more than 4,800 European or
African American individuals according to EVS. All available
family members were clinically characterized and genotyped. The
phenotypes of all MYH6 mutation carriers are given in table 1.
Alpha-myosin heavy chain (MYH6)
Family MC081 (Figure 1A). We found a heterozygous G.A
transition at position c.50 in exon 2 of MYH6 resulting in a
replacement of arginine by histidine in the N-terminal head
domain of MYH6 (R17H). The carrier (III:2) was a 10-year-old girl
with ASDII, which closed spontaneously during early childhood.
Her elder brother (III:1) was also harboring R17H and was
affected by an atrioventricular septal defect (AVSD), with a left
superior vena cava draining into the coronary sinus. He
underwent surgical AV canal closure at age of 4 years. The
mutation was also present in the younger brother (III:3) who had a
cardiac phenotype similar to that of his brother (complete AV
canal and anomalous draining of a left superior vena cava into the
coronary sinus). He had to undergo cardiac surgery within the first
year after birth. Prenatal genetic testing revealed a normal
karyotype in III:1 and III:3. There were no apparent syndromic
stigmata among the three siblings. The mutation was transmitted
by their mother who did not demonstrate any cardiac anomaly.
The maternal grandmother was reported to have a mitral valve
defect requiring cardiac surgery. The maternal grandfather died
from silicosis. The mutation affects residue R17, which is in the
highly conserved N-terminal region of a subfamily of class II
myosin heavy chains but not in class II myosin heavy chains
Table 1. Phenotype of family members with MYH6
mutations.
Pedigree ID
Nucleotide
change
Amino acid
change Phenotype
MC081 II:2 c.50G.A R17H Normal
III:1 c.50G.A R17H AVSD, left SVC to CS
III:2 c.50G.A R17H ASD
III:3 c.50G.A R17H AVSD, left SVC to CS
MC027 I:1 c.1615T.C C539R ASD
II:2 c.1615T.C C539R ASD
III:1 c.1615T.C C539R ASD
MC053 I:1 c.1628A.G K543R Normal
II:2 c.1628A.G K543R ASD
II:3 c.1628A.G K543R n.a.
III:3 c.1628A.G K543R ASD
MC078 I:1 c.3010G.T A1004S n.a. (heart murmur)
II:2 c.3010G.T A1004S Normal
II:3 c.3010G.T A1004S ASD
II:4 c.3010G.T A1004S Normal
II:6 c.3010G.T A1004S Normal
II:8 c.3010G.T A1004S ASD
AVSD – atrioventricular septal defect; SVC - superior vena cava; CS – coronary
sinus; n.a.- not assessed; The index patients are highlighted in bold letters.
doi:10.1371/journal.pone.0028872.t001
Figure 1. Family pedigrees of MYH6 mutation carriers. Squares
represent male and circles female subjects. The proband is marked by
an arrow. Plus signs and minus signs depict mutation-positive and
mutation-negative individuals, respectively. Crossed symbols represent
deceased individuals.
doi:10.1371/journal.pone.0028872.g001
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chains (see Supporting data S2A and S4). This residue is conserved
in chicken myosin-VI and included in a solved structure (PDB
code 2MYS) [13]; although the corresponding part of the structure
is not very well resolved it appears to be fully buried and mutation
to a bulky residue such as histidine would probably disrupt the
structure.
Family MC027 (Figure 1B). A heterozygous T.C transition
at position c.1615 in exon 14 of MYH6, which replaces cysteine by
arginine at residue 539 (C539R) was found in a 6-year-old girl
with ASDII (III:1). The mutation was inherited from her mother
(II:2) who also had ASDII requiring surgical closure at age of 34
years. The maternal grandmother (I:1) was also harboring C539R
and had ASDII, which was surgically closed at age of 50 years.
C539 lies within the loop of a helix-loop-helix motif that is
crucially involved in the myosin-actin interaction [13]. The
C539R mutation is located at the start of the loop and is
conserved in human myosin heavy chains class II, I, V, and XV. It
is a serine in myosin heavy chains class III, VII, IX and X, an
asparagine in myosin heavy chains class VI, and an alanine or
valine in myosin heavy chains class XVIII (see Supporting data
S2B).
Family MC053 (Figure 1C). Another mutation in this region
was a heterozygous A.G transition at nucleotide c.1628 in exon
14 resulting in a replacement of lysine by arginine at residue 543
(K543R). The carrier was a 58-year-old female (II:2) with ASDII.
The mutation was inherited from her mother whose disease status
remains unclear since she refused clinical workup. The father died
from lung cancer. The nephew (III:3) was also diagnosed with
ASDII when aged four years and harbored K543R. Similar to the
C539R mutation, the K543R mutation also affects the highly
conserved alpha myosin helix-loop-helix motif. The residue is
highly conserved in myosin heavy chain class II, and is substituted
heterogeneously in other classes, glycine, lysine and glutamine
being the most frequent residues at this position (Supporting data
S2B).
Family MC078 (Figure 1D). A heterozygous G.T
transversion in exon 22 was found at codon c.3010 of MYH6
(A1004S) in a four-year-old girl (II:8) with cribriform ASDII. The
mutation was previously described in patients with DCM [14,15].
Among seven elder siblings, one brother (II:3) harbouring A1004S
had ASDII, which was surgically closed at age of 9 years. Three
further siblings (II:2, II:4, II:6) were also positive whereas three
others (II:1, II:5, II:7) were negative for A1004S. None of them
revealed CHD. The mutation was inherited from their father. Yet,
he did not undergo echocardiography to evaluate his cardiac
phenotype. The mutation lies in the neck domain of alpha myosin
heavy chain, and is located in a portion of sequence predicted as
alpha-helicoidal according to Jpred3 [16]. The affected residue is
conserved in a subfamily of class II myosin heavy chains that
groups with MYH6 except for MYH8, which has a threonine
instead (Supporting data S2C), and it is an arginine in the other
branch of class II myosin heavy chains (MYH9, MYH10, MYH11
and MYH4; Supporting data S2C). This region has no obvious
sequence similarity to other myosin heavy chains.
Myosin-binding protein C (MYBPC3)
The A.G transition at position c.2497 in exon 26 of MYBPC3
(A833T) was found in two unrelated subjects with ASDII. The
mutation was previously identified in patients with HCM and
DCM [17,18,19]. In the present study, a 49-year-old female with
ASDII was heterozygous for A833T. Her son was also affected by
ASDII and her grandson was diagnosed with DCM at the age of 6
years. However, family members declined genetic evaluation. The
A833T mutation was also found in a 28-year-old male with ASDII
who underwent interventional closure of the defect. In addition his
father was affected by ASDII, which was also closed intervention-
ally when he was 59 years of age. However, he was negative for the
mutation, indicating that the condition of this family may not be
(or at least not solely) due to the mutation.
Novel sarcomeric gene variants of uncertain
pathogenicity and novel benign variants
In addition to the aberrations described above, we detected a
heterozygous intronic T.C variation in the MYH6 region at
position 22 relative to the start of the gene (GenBank record for
Homo sapiens chromosome 14 genomic contig, GRCh37.p2
[NT_026437]). The variation was found in a 59-year-old male
with ASDII and atrial septal aneurysm. The variant was also
found in his mother, who was affected by ASDII, but not in his
daughter who also had ASDII. Since the effect on the transcription
of the protein remains unclear, we classified it as a variant of
uncertain pathogenicity. Further, two novel synonymous variants
were found in the MYH6 gene (A1203A and I1209I) in two
Caucasian ASDII patients. According to the ESV database [12]
these variations are absent in more than 2,000 European
Americans but represent polymorphism among African Americans
with a prevalence of 1.8% and 2.2%, respectively (see supporting
data S2). Neither novel variations nor known cardiomyopathy-
related mutations were found in MYH7, TNNT2, TNNI3, TNNC1,
ACTC1, MYL2, MYL3, CSRP3, TCAP, TPM1 or in the TTN kinase
region.
Discussion
We employed an established array based sequence analysis tool
developed for genetic diagnosis of familial HCM. As reported
previously, the accuracy of the HCM1 array exceeds 99% and is
comparable to that of capillary sequencing [20]. Similar
performances were also found for the HCM2 array (unpublished
data). Although array-based resequencing increases the number of
genes that can be analyzed simultaneously, more efficient high-
throughput DNA sequencing technologies have emerged during
the last years commonly referred to as next generation sequencing
(NGS). These technologies are based on massive parallel
sequencing of millions of DNA templates through cycles of
enzymatic treatment and image-based data acquisition [21].
Although the dissemination of NGS into the clinical diagnostic
realm is in its early stages, first approaches in genetic diagnostics of
cardiac diseases by NGS seem quite promising [22] and could also
be used in the future for cases with atrial septal defects in order to
identify novel genes. In the present study we were only able to
analyze the coding regions of 13 sarcomeric genes that are covered
by the two arrays. However, we believe it is a sufficient strategy to
investigate the hypothesis if sarcomeric gene mutations are related
to human ASDII. Thirty-one carefully selected probands with
proven familial ASDII from two clinical referral centers were
included in the study after exclusion of mutations in NKX2.5 and
GATA4 [23].
In four out of 31 probands (13%) mutations in MYH6 were
identified, whereas no mutations were found in 11 other
sarcomeric genes. MYH6 encodes alpha-myosin heavy chain
expressed in the developing atria [24]. Rutland et al. showed that
knockdown of MYH6 in chick embryos resulted in inhibition of
atrial septal morphogenesis [25]. Subsequent structural analysis
indicated that the interaction of normal alpha-actin and mutated
alpha-myosin may perturb sarcomere formation. Therefore, the
authors proposed that disturbed actin-myosin assembly may lead
Sarcomeric Gene Mutation in ASDII
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present study, three out of four ASDII-related MYH6 mutations
are located in the head domain of alpha-myosin responsible for
actin-binding. In contrast, mutational analyses of MYH6 in
probands with cardiomyopathy found that the majority of
mutations were located in the myosin rod or neck [14,15,26]
whereas only very few were detected in the head (Figure 2) [15]. In
a recent study, Granados-Riveron and colleagues found three out
of four MYH6 mutations in the rod domain mutations among 55
probands with ASDII. Five additional MYH6 mutations were
identified among 415 subjects with diverse CHD [10]. Therefore,
one may assume that MYH6 mutations are most frequently
present in ASDII patients than in subjects with other CHD, with a
substantial fraction located in the head domain (Figure 2).
We used control genotyping, cosegregation analysis, sequence
homology assessment, and structure analyses to evaluate the
potential pathogenic impact of the MYH6 mutations. In addition
all potential mutations were checked in the EVS database [12].
Although the mutations mostly cosegregated with CHD in the
families, we also observed the common CHD features of decreased
penetrance and variability of expressivity. In family MC081, the
R17H mutation seems to be associated with a dominant trait and
incomplete disease penetrance. The types of observed cardiac
malformations were ASDII and non-syndromic AVSD – a CHD
which is mainly attributed to defects of endocardial cushion
formation. To our knowledge, AVSD had never been previously
associated with sarcomeric gene mutations. In the study by
Granados-Riveron et al., no MYH6 mutations were found in 10
patients with AVSD [10]. On the molecular level the replacement
of arginine by histidine maintains a positively charged residue but
only arginine (and not histidine) can establish hydrogen bonds to
negatively charged residues. The R17H mutation was predicted to
be ‘‘probably damaging’’ by the PolyPhen-2 software tool for
prediction of effects of missense mutations [27] and was not found
among 4,800 American individuals of European or African
descent [12]. The C539R and K543R mutations are both located
right in the middle loop of the helix-loop-helix that represents a
major participant in the interface of actin-myosin according to
Holmes et al. [13] Whereas all probands carrying C539R had
ASDII, the K543R mutation seems to be associated with
incomplete disease penetrance. Both mutations are very likely to
modify the interaction of alpha-myosin with actin according to the
model of their interaction [13]. The C539R mutation results in a
much longer side chain, which likely collides with a neighboring
helix and may produce an opening of the helix-loop-helix
according to the structures of either the chicken myosin-V (39%
Figure 2. Localization of all so far detected MYH6 mutations. Centrally shown are the three main domains of alpha-myosin heavy chain (head,
neck, and rod). Identified mutations in patients with cardiomyopathy are shown above the protein while mutations in patients with congenital heart
disease (CHD) are shown below. Mutations found in this study are underlined. The interaction sites for alpha-actin, adenosine triphosphate (ATP), and
regulatory myosin light chain (RLC) as well as the known coiled coil structure are indicated. The human cardiac phenotypes to each mutation are
given in the table below. FDCM: familial DCM; IDCM: idiopathic DCM; TA: tricuspid atresia; TGA: transposition of the great arteries; PFO: patent
foramen ovale; SAR: subaortic rim; AS: Aortic stenosis.
doi:10.1371/journal.pone.0028872.g002
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(81% identical, not shown). The K543R mutation results in the
substitution of a side chain for a slightly bulkier one pointing in the
direction of actin, according to the definition of the myosin-actin
interface [13], and therefore may compromise the interaction
(supporting data S5b). Whereas C539R was predicted to be
probably damaging, the K543R mutation was predicted as benign
according to the PolyPhen-2 tool. Yet, both mutations were
excluded in 185 controls in the present study and among 4,800
individuals according to EVS [12]. The A1004S mutation was
previously identified in three patients with sporadic DCM and one
patient with familial DCM [14,15]. In the present study, we could
not find evidence for DCM in any patient harboring A1004S. Yet
a significant portion of A1004 carriers had a normal cardiac
phenotype. This mutation is the only one located in the myosin
neck, which is predicted to be mostly alpha-helicoidal but whose
detailed structure is so far unknown. A 3D structure model for the
chicken homolog MYH11 based on a low resolution image from
cryomicroscopy covers up to the first 100 amino acids of the
myosin rod suggesting two long homodimerizing alpha helices [28]
but the region homologous to A1004 is not part of the model.
Nevertheless, this model and a previous study show that the
integrity of the myosin rod is important for homodimerization and
regulation myosin [29]. The mutations in this region may
therefore impair the homodimerization properties of MYH6.
However, the fact that the A1004S mutation was now found in
four different families with different cardiac diseases in addition to
healthy family relatives raises some doubt about the true
pathogenicity of this variation. According to EVS the A1004S
variation has a frequency of slightly more than 0.1% in Europeans
(see supporting data S1). Even less certain is the role of the
MYBPC3-A833T variant, which was found in different studies
revealing incomplete familial segregation with HCM and DCM
[17,18,19]. Although we found a grandson of the proband with
ASDII to be affected by cardiomyopathy, we were not able to
investigate his genetic status. The A833T variation is present in
0.3% of European Americans according to EVS [12].
A number of MYH6 mutations are related to myocardial
diseases as shown in Figure 2. Obviously, effects of these mutations
can manifest during development, causing congenital heart
malformations, whereas others cause cardiomyopathy during
postnatal life. But the mechanisms underlying this expression
diversity still have to be elucidated. Interestingly, mutations in the
other main cardiac myosin heavy chain isoform, beta-myosin
(MYH7), can also lead to phenotypically distinct diseases [8,11,30].
Besides familial HCM, DCM and LVNC, Laing early onset distal
myopathy and myosin storage myopathy can be caused by MYH7
mutations. However, no such mutations could be found in ASDII
patients, which was confirmed by the present study. Expression
differences of the two myosin isoforms in cardiac muscle may
provide a hint why only MYH6 is associated with atrial septal
defects. As shown in earlier studies, alpha-myosin is expressed in
human atria but not in ventricles whereas beta-myosin is expressed
exclusively in the ventricles [24,31]. To conclude, in the present
study we identified three ASDII related MYH6 mutations that
were not reported before. Interestingly, all mutations are localized
in the motor region of alpha-myosin involved in myosin actin
interaction. Our study confirms the assumption that ASDII lies
within the diverse spectrum of structural heart anomalies that may
be related to sarcomeric gene defects in an autosomal dominant
manner. Among various sarcomeric cardiomyopathy disease genes
the alpha-myosin heavy chain seems to play a major role in ASDII
etiology.
Materials and Methods
Patients and clinical evaluation
Thirty-one ASDII patients with a positive family history (at least
one relative with ASDII or other congenital septation defect) were
included in the study. All patients were of European (Caucasian)
origin including ancestors from France, Germany, Spain and
Poland. Patients were attending either the Department of
Congenital Heart Disease/Pediatric Cardiology at the Deutsches
Herzzentrum Berlin (German Heart Institute Berlin), Germany, or
were part of the French National Registry of Familial Congenital
Heart Defects based at the Groupe Hospitalier Est in Lyon,
France. All patients (or legal guardians of minors) gave written
informed consent after approval of the institutional review board
of the Charite - Universita ¨tsmedizin Berlin. One hundred eighty
five Caucasian (and therefore ethnically matched) control patients
were selected; 96 of them underwent transesophageal echocardi-
ography to exclude atrial shunts.
Genetic analysis
Array-based resequencing (ABR) was used to analyze all exonic
regions and flanking intronic sequences of 16 genes. Two different
Affymetrix (High Wycombe, UK) arrays were deployed covering a
total of 13 sarcomeric and three non-sarcomeric hypertrophic
cardiomyopathy (HCM) disease genes: the first array (referred to
as the ‘‘HCM1 array’’) covers the three major HCM disease genes
MYH7, MYBPC3, and TNNT2. ABR using the HCM1 array was
conducted as described [20], with two exceptions where Long-
AmpH Taq polymerase was used for DNA amplification, and
SeqC software (JSi Medical Systems, Kippenheim, Germany) was
used subsequently to GSEQ 4.1 software (Affymetrix) to detect
mutations. Essentially the same resequencing protocol was used for
the second array (referred to as the ‘‘HCM2 array’’) that was
designed to analyze ten sarcomeric and sarcomere-associated
genes (TCAP, TNNI3, MYH6, TPM1, MYL2, CSRP3, ACTC1,
MYL3, TNNC1, TTN kinase region) and three non-sarcomeric
genes (GLA, CRYAB, PRKAG2). All possibly disease-causing
mutations were confirmed in the index patient (and followed up
in relatives) by Sanger sequencing following standard protocols.
Details on the primers and protocols used are available upon
request.
Homology analysis of human myosin heavy chain
proteins and homologs of solved structure
We found that the orthologs of human MYH6 were not useful
for the analysis of residue conservation since they are not
divergent enough from the human sequence with which they
have identity percentages ranging from 83% of Danio rerio
MYH6 to 97% of murine MYH6 when comparing full length
sequences. Accordingly, the multiple sequence alignment of
these sequences indicated that all mutations described here were
fully conserved (data not shown). To gain a better idea of residue
conservation we retrieved from the Entrez gene database the
records of the 37 human genes for myosin heavy chains plus four
homologs of solved structure (Supporting data S3). One human
gene is a pseudogene (MYH16). The other genes coded for
protein products whose sequences were obtained from the
Entrez protein database and aligned using the MUSCLE
algorithm [32] via the EBI server (Supporting data S2). A
phylogenetic tree of the resulting alignment was obtained using
ClustalX [33] and represented with NJplot [34] (Supporting data
S4), indicating good agreement of the alignment with the known
myosin classes.
Sarcomeric Gene Mutation in ASDII
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Since we were interested in the assessment of the molecular
effect of the MYH6 mutants we represented them using the
structure of the myosin head domain of chicken myosin-V (PDB
code 1OE9) [35]. These sequences are 39% identical over their
myosin head domains and therefore very likely to have similar
structures. Moreover, after alignment we observed that the
chicken protein shares the residues, the object of this study that
lie in the myosin head domain. These residues were highlighted in
the corresponding structure and the effects of mutations were
studied simply by substituting the corresponding side chains
keeping their original direction (see Supporting data S5).
Structures were displayed and manipulated using the PyMOL
Molecular Graphics System software (DeLano Scientific, Palo
Alto, California).
Supporting Information
Data S1 Gene variants identified in 31 index patients with
familial ASDII.
(PDF)
Data S2 Fragments of a multiple sequence alignment of all 37
human myosin heavy chains with four homologs of known
structure. Sequence identifiers and other sequence information are
available in Supporting data 1. The yellow and green blocks
represent alpha-helix and beta-sheet in solved structures. (A)
Region around R17. (B) Region around C539 and K543. (C)
Region around A1004.
(PDF)
Data S3 Database record identifiers and annotations of the 37
human genes for myosin heavy chains and of four homologs of
solved structure.
(PDF)
Data S4 Phylogenetic tree of the sequences aligned in the
supporting data 1. Classes are indicated.
(PDF)
Data S5 Zoomed view of the structure from chicken myosin V
(PDB:1OE9) [35]. The structure is displayed as a ribbon with the
helix-loop-helix colored in red. (A) Original residues equivalent to
human MYH6-K543 and MYH6-C539 are highlighted with side
chains represented as sticks. These residues are conserved in the
structure represented. (B) For illustration, mutants are represented
by simple substitution of side chains without modifying the
structure. R539 collides with the nearby helix since it is bulkier
than the wild type residue. R543, also with a larger side chain than
that of the wild type residue, points to the surface of interaction
with actin according to a model by Holmes et al. [13]. This
substitution may compromise the interaction between actin and
myosin heavy chain.
(PDF)
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